Thus far, the vaccine has reduced mortality by 50% (Gardner, 2008). A secondvaccine, which is believed to be an improvement over Neu Vax, is still being tested in mice.it also targets overexpressive HER2/neu cell,with an immune system stimulant.
Thus far, the vaccine has reduced mortality by 50% (Gardner, 2008). A secondvaccine, whichis believed to be an improvement over Neu Vax, is still being tested in mice.it also targets overexpressive HER2/neu cell,with an immune system stimulant.